biostudies-literatureChen HYInnovative Research Group Project of the National Natural Science Foundation of China33https://www.ebi.ac.uk/biostudies/studies/S-EPMC7879534biostudies-literatureUnknown13(1)<h4>Background</h4>Although R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) remains the standard chemotherapy regimen for diffuse large B cell lymphoma (DLBCL) patients, not all patients are responsive to the scheme, and there is no effective method to predict treatment response.<h4>Methods</h4>We utilized 5hmC-Seal to generate genome-wide 5hmC profiles in plasma cell-free DNA (cfDNA) from 86 DLBCL patients before they received R-CHOP chemotherapy. To investigate the correlation between 5hmC modifications and curative effectiveness, we separated patients into training (n = 56) and validation (n = 30) cohorts and developed a 5hmC-based logistic regression model from the training cohort to predict the treatment response in the validation cohort.<h4>Results</h4>Clinical epigenetics5-Hydroxymethylcytosine profiles of cfDNA are highly predictive of R-CHOP treatment response in diffuse large B cell lymphoma patients.PMC7879534818001953147129981522046Liu HLiu JXu NHe CLi FChen LQin YZhang LWang JLi WXiao XBHong YHe XHZhu HCChen HYYang PYang ZRPang MYan CJing HMLin JZhang WLfalse5-Hydroxymethylcytosine profiles of cfDNA are highly predictive of R-CHOP treatment response in diffuse large B cell lymphoma patients.<h4>Background</h4>Although R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) remains the standard chemotherapy regimen for diffuse large B cell lymphoma (DLBCL) patients, not all patients are responsive to the scheme, and there is no effective method to predict treatment response.<h4>Methods</h4>We utilized 5hmC-Seal to generate genome-wide 5hmC profiles in plasma cell-free DNA (cfDNA) from 86 DLBCL patients before they received R-CHOP chemotherapy. To investigate the correlation between 5hmC modifications and curative effectiveness, we separated patients into training (n = 56) and validation (n = 30) cohorts and developed a 5hmC-based logistic regression model from the training cohort to predict the treatment response in the validation cohort.<h4>Results</h4>2021-01-01T00:00:00Z2021 Feb2026-05-04T18:27:20.384Z2021-02-21T10:46:59ZS-EPMC78795343357370310.1186/s13148-020-00973-8